Capital constraints. Most specifically, human capital. mRNA production methods, including for critical precursors, are complicated. There is a limited number of people who can build and monitor the productions systems.
I believe the issue is that too many people fail to get vaccinated so it's challenging. Requiring boosters might also convert small numbers of people who got a vaccine one to not get it subsequent times.
If we don’t significantly vaccinate much of the rest of the world, my expectation is a continued high rate of variant creation as well as continued economic instability due to logistics disruption.
Intellectual property rights.
It's not a "good" reason. But it's a reality that needs to be overcome.
https://www.reuters.com/business/healthcare-pharmaceuticals/...
https://www.democracynow.org/2021/6/22/headlines/south_afric...
Germany doesn't want the Pfizer vaccine made freely: https://www.reuters.com/business/healthcare-pharmaceuticals/...
and by some co-incidence, this is good for German money: https://www.reuters.com/article/us-germany-economy-biontech-...